
Jonathan D. Armstrong
Examiner (ID: 4864, Phone: (571)270-7339 , Office: P/3645 )
| Most Active Art Unit | 3645 |
| Art Unit(s) | 3645 |
| Total Applications | 503 |
| Issued Applications | 231 |
| Pending Applications | 107 |
| Abandoned Applications | 202 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 14273745
[patent_doc_number] => 20190134157
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-05-09
[patent_title] => ANTIBACTERIAL AGENT FOR TREATING INFECTIOUS DISEASES OF BACTERIAL ORIGIN
[patent_app_type] => utility
[patent_app_number] => 16/238686
[patent_app_country] => US
[patent_app_date] => 2019-01-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14790
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 59
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16238686
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/238686 | ANTIBACTERIAL AGENT FOR TREATING INFECTIOUS DISEASES OF BACTERIAL ORIGIN | Jan 2, 2019 | Abandoned |
Array
(
[id] => 14780711
[patent_doc_number] => 20190265253
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-08-29
[patent_title] => METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE
[patent_app_type] => utility
[patent_app_number] => 16/237479
[patent_app_country] => US
[patent_app_date] => 2018-12-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 140974
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 289
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16237479
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/237479 | Methods and compositions for diagnosis and prognosis of renal injury and renal failure | Dec 30, 2018 | Issued |
Array
(
[id] => 16511555
[patent_doc_number] => 20200390812
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-12-17
[patent_title] => METHOD FOR NK CELL TRANSDUCTION
[patent_app_type] => utility
[patent_app_number] => 16/954912
[patent_app_country] => US
[patent_app_date] => 2018-12-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13435
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16954912
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/954912 | Method for NK cell transduction | Dec 18, 2018 | Issued |
Array
(
[id] => 17350067
[patent_doc_number] => 11224685
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-01-18
[patent_title] => Self-regulating device for modulating inflammation
[patent_app_type] => utility
[patent_app_number] => 16/156277
[patent_app_country] => US
[patent_app_date] => 2018-10-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 36
[patent_figures_cnt] => 41
[patent_no_of_words] => 17663
[patent_no_of_claims] => 5
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 159
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16156277
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/156277 | Self-regulating device for modulating inflammation | Oct 9, 2018 | Issued |
Array
(
[id] => 14069415
[patent_doc_number] => 20190083595
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-03-21
[patent_title] => METHODS FOR TREATING NETOSIS AND NEUTROPHIL ACTIVATION
[patent_app_type] => utility
[patent_app_number] => 16/134070
[patent_app_country] => US
[patent_app_date] => 2018-09-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 51990
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -28
[patent_words_short_claim] => 22
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16134070
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/134070 | Methods for treating netosis and neutrophil activation | Sep 17, 2018 | Issued |
Array
(
[id] => 19439939
[patent_doc_number] => 12090165
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-09-17
[patent_title] => Methods for reducing or shutting down lactation in non-human mammals and reagents therefor
[patent_app_type] => utility
[patent_app_number] => 16/646246
[patent_app_country] => US
[patent_app_date] => 2018-09-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 29
[patent_figures_cnt] => 18
[patent_no_of_words] => 16944
[patent_no_of_claims] => 10
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 132
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16646246
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/646246 | Methods for reducing or shutting down lactation in non-human mammals and reagents therefor | Sep 11, 2018 | Issued |
Array
(
[id] => 18701594
[patent_doc_number] => 11788093
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-10-17
[patent_title] => Chimeric antigen receptor t-cells expressing interleukin-8 receptor
[patent_app_type] => utility
[patent_app_number] => 16/645154
[patent_app_country] => US
[patent_app_date] => 2018-09-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 38
[patent_figures_cnt] => 28
[patent_no_of_words] => 20854
[patent_no_of_claims] => 12
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 25
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16645154
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/645154 | Chimeric antigen receptor t-cells expressing interleukin-8 receptor | Sep 5, 2018 | Issued |
Array
(
[id] => 14849757
[patent_doc_number] => 10413584
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2019-09-17
[patent_title] => Peptides having immunomodulatory properties
[patent_app_type] => utility
[patent_app_number] => 16/116619
[patent_app_country] => US
[patent_app_date] => 2018-08-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 4
[patent_figures_cnt] => 5
[patent_no_of_words] => 20982
[patent_no_of_claims] => 19
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 36
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16116619
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/116619 | Peptides having immunomodulatory properties | Aug 28, 2018 | Issued |
Array
(
[id] => 18825431
[patent_doc_number] => 11840702
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-12-12
[patent_title] => Adenovirus armed with bispecific T cell activator
[patent_app_type] => utility
[patent_app_number] => 16/641696
[patent_app_country] => US
[patent_app_date] => 2018-08-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 74
[patent_figures_cnt] => 73
[patent_no_of_words] => 33737
[patent_no_of_claims] => 9
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 96
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16641696
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/641696 | Adenovirus armed with bispecific T cell activator | Aug 27, 2018 | Issued |
Array
(
[id] => 13790775
[patent_doc_number] => 20190008926
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-01-10
[patent_title] => PHARMACEUTICAL COMPOSITIONS AND METHODS FOR FABRICATION OF SOLID MASSES COMPRISING POLYPEPTIDES AND/OR PROTEINS
[patent_app_type] => utility
[patent_app_number] => 16/112558
[patent_app_country] => US
[patent_app_date] => 2018-08-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13477
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 43
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16112558
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/112558 | Pharmaceutical compositions and methods for fabrication of solid masses comprising polypeptides and/or proteins | Aug 23, 2018 | Issued |
Array
(
[id] => 17393393
[patent_doc_number] => 11242395
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-02-08
[patent_title] => Anti-CD137 molecules and use thereof
[patent_app_type] => utility
[patent_app_number] => 16/108018
[patent_app_country] => US
[patent_app_date] => 2018-08-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 55
[patent_figures_cnt] => 38
[patent_no_of_words] => 34034
[patent_no_of_claims] => 29
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 56
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16108018
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/108018 | Anti-CD137 molecules and use thereof | Aug 20, 2018 | Issued |
Array
(
[id] => 19089709
[patent_doc_number] => 11951128
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-04-09
[patent_title] => Compositions and methods for the isolation and/or generation of specific CD4+ and CD8+ T-cell subsets
[patent_app_type] => utility
[patent_app_number] => 16/635015
[patent_app_country] => US
[patent_app_date] => 2018-08-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 28
[patent_figures_cnt] => 36
[patent_no_of_words] => 22121
[patent_no_of_claims] => 8
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 47
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16635015
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/635015 | Compositions and methods for the isolation and/or generation of specific CD4+ and CD8+ T-cell subsets | Aug 1, 2018 | Issued |
Array
(
[id] => 13823995
[patent_doc_number] => 20190015482
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-01-17
[patent_title] => PHARMACEUTICAL COMPOSITIONS AND METHODS FOR FABRICATION OF SOLID MASSES COMPRISING TNF-INHIBITING ANTIBODIES
[patent_app_type] => utility
[patent_app_number] => 16/050995
[patent_app_country] => US
[patent_app_date] => 2018-07-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13534
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -27
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16050995
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/050995 | Pharmaceutical compositions and methods for fabrication of solid masses comprising TNF-inhibiting antibodies | Jul 30, 2018 | Issued |
Array
(
[id] => 16466786
[patent_doc_number] => 20200368323
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-11-26
[patent_title] => PEGYLATED INTERFERON LAMBDA HAVING HIGH ORAL BIOAVAILABILITY AND METHOD FOR PREPARATION THEREOF
[patent_app_type] => utility
[patent_app_number] => 16/617261
[patent_app_country] => US
[patent_app_date] => 2018-07-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7898
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -7
[patent_words_short_claim] => 95
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16617261
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/617261 | PEGYLATED INTERFERON LAMBDA HAVING HIGH ORAL BIOAVAILABILITY AND METHOD FOR PREPARATION THEREOF | Jul 22, 2018 | Abandoned |
Array
(
[id] => 15631947
[patent_doc_number] => 10588941
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2020-03-17
[patent_title] => Modulation of CCR10 signals for treatment of skin and intestinal inflammatory diseases and infection
[patent_app_type] => utility
[patent_app_number] => 16/040592
[patent_app_country] => US
[patent_app_date] => 2018-07-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 25
[patent_figures_cnt] => 25
[patent_no_of_words] => 31242
[patent_no_of_claims] => 2
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 40
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16040592
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/040592 | Modulation of CCR10 signals for treatment of skin and intestinal inflammatory diseases and infection | Jul 19, 2018 | Issued |
Array
(
[id] => 13867563
[patent_doc_number] => 20190030122
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-01-31
[patent_title] => CYTOKINE MODULATION
[patent_app_type] => utility
[patent_app_number] => 16/040412
[patent_app_country] => US
[patent_app_date] => 2018-07-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 32410
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -25
[patent_words_short_claim] => 22
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16040412
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/040412 | Cytokine modulation | Jul 18, 2018 | Issued |
Array
(
[id] => 16665125
[patent_doc_number] => 10934358
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-03-02
[patent_title] => Anti-DEspR inhibitors as therapeutics for inhibition of pathological angiogenesis and tumor cell invasiveness and for molecular imaging and targeted delivery
[patent_app_type] => utility
[patent_app_number] => 16/026467
[patent_app_country] => US
[patent_app_date] => 2018-07-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 42
[patent_figures_cnt] => 140
[patent_no_of_words] => 60469
[patent_no_of_claims] => 16
[patent_no_of_ind_claims] => 5
[patent_words_short_claim] => 147
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16026467
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/026467 | Anti-DEspR inhibitors as therapeutics for inhibition of pathological angiogenesis and tumor cell invasiveness and for molecular imaging and targeted delivery | Jul 2, 2018 | Issued |
Array
(
[id] => 13440909
[patent_doc_number] => 20180271997
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-09-27
[patent_title] => Methods and Reagents to Treat Tumor and Cancer
[patent_app_type] => utility
[patent_app_number] => 16/004415
[patent_app_country] => US
[patent_app_date] => 2018-06-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9356
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -8
[patent_words_short_claim] => 20
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16004415
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/004415 | Methods and Reagents to Treat Tumor and Cancer | Jun 9, 2018 | Abandoned |
Array
(
[id] => 13826651
[patent_doc_number] => 20190016810
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-01-17
[patent_title] => METHODS FOR TREATING OR PREVENTING GRAFT-VERSUS-HOST DISEASE INVOLVING THE ADMINISTRATION OF ANTI-CCR5 RECEPTOR AGENTS
[patent_app_type] => utility
[patent_app_number] => 15/977929
[patent_app_country] => US
[patent_app_date] => 2018-05-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 18902
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15977929
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/977929 | METHODS FOR TREATING OR PREVENTING GRAFT-VERSUS-HOST DISEASE INVOLVING THE ADMINISTRATION OF ANTI-CCR5 RECEPTOR AGENTS | May 10, 2018 | Abandoned |
Array
(
[id] => 13548957
[patent_doc_number] => 20180326026
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-11-15
[patent_title] => METHOD AND COMPOSITION FOR TREATING SARCOPENIA
[patent_app_type] => utility
[patent_app_number] => 15/977587
[patent_app_country] => US
[patent_app_date] => 2018-05-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6287
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15977587
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/977587 | Method and composition for treating sarcopenia | May 10, 2018 | Issued |